CHU de Liege /ID# 263108

Liège 4000

0 studies enrolling now · 1 studies all time

What they study most

Moderate Plaque Psoriasis

Studies at this site

• A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) — Completed